Pegylated Recombinant Human Arginase (rhArg-peg$_{5,000mw}$) Inhibits the *In vitro* and *In vivo* Proliferation of Human Hepatocellular Carcinoma through Arginine Depletion

Paul Ning-Man Cheng,[1,2] Tin-Lun Lam,[1] Wai-Man Lam,[1] Sam-Mui Tsui,[1] Anthony Wai-Ming Cheng,[1] Wai-Hung Lo,[1] and Yun-Chung Leung[1]

[1]Cancer Drug R&D Centre and Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, and [2]Bio-Cancer Treatment International Limited, Bio-Informatics Centre, Hong Kong Science Park, Hong Kong, China

Abstract

Hepatocellular carcinoma (HCC) is believed to be auxotrophic for arginine through the lack of expression of argininosuccinate synthetase (ASS). The successful use of the arginine-depleting enzyme arginine deiminase (ADI) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy. Nevertheless, many ASS-positive HCC cell lines are found to be resistant to ADI treatment, although most require arginine for proliferation. Thus far, an arginine-depleting enzyme for killing ASS-positive tumors has not been reported. Here, we provide direct evidence that recombinant human arginase (rhArg) inhibits ASS-positive HCCs. All the five human HCC cell lines we used were sensitive to rhArg but ADI had virtually no effect on these cells. They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS. Transfection of HCC cells with OTC resulted in resistance to rhArg. Thus, OTC expression alone may be sufficient to induce rhArg resistance in ASS-positive HCC cells. This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated arginine depletion. Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes. We have also shown that the rhArg native enzyme and the pegylated rhArg (rhArg-peg$_{5,000mw}$) gave similar anticancer efficacy *in vitro*. Furthermore, the growth of the OTC-deficient Hep3B tumor cells (ASS-positive and ADI-resistant) in mice was inhibited by treatment with rhArg-peg$_{5,000mw}$, which is active alone and is synergistic in combination with 5-fluorouracil. Thus, our data suggest that rhArg-peg$_{5,000mw}$ is a novel agent for effective cancer therapy. [Cancer Res 2007;67(1):309–17]

Introduction

Arginine has been known to influence the growth of transplantable mice tumor since 1930 (1). Diet supplemented with arginine

enhances tumor growth in mice. Conversely, dietary restriction of arginine inhibits growth of metastatic tumor (2). Arginine is an indispensable amino acid to children but a semi-essential amino acid in adult humans, involved in the synthesis of a wide range of peptides and proteins, production of creatine and nitric oxide, and a myriad of metabolic pathways and cellular events (3). It is also a precursor of proline, polyamines, glutamine, glutamate, and other neurotransmitters, such as γ-aminobutyric acid. It also serves as a substrate for two important enzymes, arginase and nitric oxide synthetase.

The body obtains arginine from various sources, including dietary intake, muscle degradation with the proteosomal/ubiquitin pathway, and the "intestinal-renal axis." In the small bowel, ornithine transcarbamylase (OTC) catalyzes the synthesis of citrulline from ornithine and carbamoyl phosphate. In turn, this citrulline is converted to arginine in the proximal renal tubules by argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL), the so called "intestinal-renal axis," which accounts for up to 60% of all arginine endogenously generated in humans. OTC is expressed largely in the small bowel and liver. Despite its high degree of versatility within the cell, arginine is still regarded as a semi-essential amino acid in adult humans because somatic cells can synthesize it from citrulline via ASS and ASL, both of which are ubiquitous in somatic cells (1). This is because demand outstrips supply at certain times during growth and development; equally, the growth of a tumor can become a stress, which is relieved by supplementation of arginine (4).

The arginine-degrading enzyme in the urea cycle is arginase, the *in vitro* anticancer property of which has been well documented since the 1960s (5). Arginase enzymatically converts arginine to ornithine and urea. Currie et al. (6) showed that arginase released from lipopolyssacharide and zymosan-stimulated macrophages can be responsible for the death of V79 Chinese hamster lung cells, L5178Y lymphoma cells, and HSN hooded rat sarcoma in culture. Using murine and bovine liver arginases, Storr and Burton (7) showed the total destruction of lymphosarcoma cells when arginine was reduced to <8 μmol/L over 24 h. *In vitro* arginine depletion, either through arginase or preparation of arginine-free medium, leads to rapid tumor death in a wide range of tumor cell lines (7).

Another potent arginine-depleting enzyme is arginine deiminase (ADI), which is a microbial enzyme from *Mycoplasma* spp. The enzyme has both anti–hepatocellular carcinoma (HCC; ref. 8) and anti–malignant melanoma (4) properties. The pegylated form of ADI is now in phase II clinical trial stage, showing its strong anticancer activities against HCC and malignant melanoma (9, 10). These tumors are often dependent on exogenous arginine for

growth because the cells generally cannot internally synthesize arginine (i.e., they are, or become, auxotrophic for arginine). The mechanism of arginine auxotrophy in these tumors is likely to be complex but primarily seems to be related to the down-regulation of the *ASS* gene at the transcriptional level by inhibition of its promoter sequence through methylation (11). This selective differential requirement in arginine between most somatic cells and tumor cells, which are auxotrophic for arginine, provides a rational basis that can be thoroughly exploited to develop new treatment methods not just for HCC and malignant melanoma but also for many types of malignancies (9–11).

ASS is a key enzyme in the synthesis of arginine from citrulline. Tumors (mainly malignant melanoma and HCC) that are sensitive to arginine depletion by ADI do not express ASS (4, 12, 13). Shen et al. (14) reported that many cell lines are resistant to ADI treatment, although most require arginine for proliferation. Their results indicate that resistance to ADI treatment may correlate with cellular ASS activity, either constitutive or inducible, allowing cell survival by conversion of the product of the ADI reaction (i.e., citrulline to arginine). Wheatley (15) suggested that the enzymes involved in converting arginine from citrulline (ASS and ASL) are tightly coupled, and in cultured cells, ornithine cannot be sent on round the urea cycle and, hence, is an end product except in some freshly isolated liver cells or some minimum deviation hepatomas.

Arginase converts arginine to ornithine and urea. Despite its strong *in vitro* anticancer properties, arginase was never seriously considered as a potential drug candidate for the treatment of human cancers for several reasons, including its much lower affinity for arginine (K_m, 6 mmol/L for the native enzyme; K_m, 12 mmol/L for the pegylated enzyme) at physiologic pH (16), a pH optimum of 9.6, and short circulatory half-life (a few minutes). These have been considered serious shortcomings since the 1980s, with the report from Savoca et al. (17) who observed no antitumor activity of bovine liver arginase in mice with Taper liver cancer. Other investigators also gave very negative reports on arginase (18). It is important to recognize, however, that these *in vivo* data were generated with bovine and murine arginases, which have different biochemical properties compared with the human liver arginase. Nowadays, one can use recombinant human arginase, which was not available for study until the advent of recombinant DNA technology (19).

We have previously shown (20) that arginine depletion with endogenous human hepatic arginase released from transhepatic arterial embolization could induce a systemic anti-HCC response. This convinced us that recombinant human arginase (rhArg) given exogenously, after suitable modification to lengthen its half-life such as pegylation, could induce a similar antitumor response. In the present study, the use of rhArg produced in a *Bacillus subtilis* expression system (21) is described. The isolated and purified enzyme is covalently attached via a succinamide propionic acid (SPA) linker to polyethylene glycol (PEG) of molecular weight 5,000. Unlike many other pegylated enzymes, this pegylated rhArg (rhArg-peg$_{5,000mw}$) was fully active. The K_m value for arginine as the substrate of the pegylated rhArg was also much smaller (K_m = 2.9 mmol/L) than that of the pegylated bovine liver arginase (K_m = 12 mmol/L). Subsequently, the pegylated rhArg was found to have an *in vivo* half-life of ~3 days while maintaining sufficient enzyme catalytic activity at physiologic pH. The biochemical characteristics as well as the production methods have already been reported (21).

Using our rhArg and pegylated rhArg, we have done experiments to (*a*) compare the *in vitro* antitumor activities between rhArg and pegylated rhArg; (*b*) compare the *in vitro* antitumor activity of the rhArg native enzyme with that of the ADI native enzyme; (*c*) work out why some cancer cell lines are rhArg sensitive but ADI resistant *in vitro*; and (*d*) test the *in vivo* antitumor activity of rhArg-peg$_{5,000mw}$, alone and in combination with 5-fluorouracil (5-FU), in nude mice bearing an ADI-resistant HCC xenograft. The questions "Is rhArg able to inhibit ASS-positive HCCs that cannot be treated by ADI?" and "Is rhArg-peg$_{5,000mw}$ an effective anticancer agent?" have been investigated in this report.

Materials and Methods

Materials. Materials not specified here were obtained from Sigma Chemical Company (St. Luis, MO). Cell proliferation kit with 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2*H*-tetrazolium (MTS) reagent was obtained from Promega (Madison, WI). All cell culture media and sera were purchased from Invitrogen Life Technologies, Inc. (San Diego, CA). Expression plasmid pcDNA3 was from Invitrogen (San Diego, CA). The *Mycoplasma arginini* ADI native enzyme was generously provided by Professor B.H. Min (Department of Pharmacology and BK21 Program for Medical Sciences, College of Medicine, Korea University, Seoul, South Korea). Methoxypolyethylene glycol succinimidyl propionate (mPEG-SPA; MW 5,000) was purchased from Nektar Therapeutics (Huntsville, AL).

The cell line Huh7 was provided by Professor R. Poon (Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China). All other cancer cell lines were purchased from American Type Culture Collection (Manassas, VA). The details of the cell lines are as follows: HepG2 (HBV-negative hepatoblastoma, HB-8065); Hep3B (HBsAg-positive HCC, HB-8064); PLC/PRF/5 (primary hepatoma cells, contain hepatitis B, express hepatitis B virus surface antigen, CRL-8024); SK-HEP-1 (liver adenocarcinoma, HTB-52); Huh7 (well-differentiated HBsAg-negative HCC); A549 (lung carcinoma, CCL-185); WiDr (colorectal adenocarcinoma, CCL-218); SK-MEL-28 (malignant melanoma, HTB-72); and HeLa (cervix adenocarcinoma, CCL-2).

Preparation of rhArg and rhArg-peg$_{5,000mw}$. Recombinant human arginase (rhArg) was obtained by producing the His-tagged human arginase I (liver arginase) enzyme in *B. subtilis* (21). A coupled spectrophotometric assay was used to determine arginase activity as described by Ikemoto et al. (22). The specific activity of the purified enzyme was ~400 IU/mg protein. One international unit of arginase is defined as the amount of enzyme that can produce 1 μmol urea/min at 30°C, pH 8.5.

The purified enzyme (native rhArg) was used directly for conjugation with PEG as follows: mPEG-SPA of MW 5,000 was covalently attached to arginase with the same methods that were used for formulating ADI with PEG (12). The resulting PEG-formulated (pegylated) arginase was termed rhArg-peg$_{5,000mw}$ (Fig. 1). Only the purified *M. arginini* ADI (23) native enzyme (without pegylation) was used in our studies. The specific activity of the purified ADI was ~46 units/mg protein. One unit of the ADI native enzyme is the amount of enzyme activity that converts 1 μmol of arginine to 1 μmol of citrulline per minute at 37°C under the assay conditions (23).

To determine the number of PEG per arginase molecule, a PEG standard curve was constructed by the colorimetric assay as described by Nag et al. (24). Briefly, free PEG was detached from rhArg-peg$_{5000mw}$ by incubating with proteinase. The amount of free PEG in the resulting mixture was determined by comparing to the PEG standard curve. The number of PEG molecules attached to the primary amines of arginase was calculated by the mole ratio of free PEG and rhArg-peg$_{5,000mw}$. The number of PEG per rhArg was estimated to be 10 to 12.

Cell culture and cell proliferation assay. The cells were maintained either in DMEM or RPMI 1640 supplemented with 10% (v/v) fetal bovine serum and 100 units/mL penicillin/streptomycin. Cells (2.5×10^3) in a volume of 100 μL of culture medium were seeded to each well of a 96-well plate and incubated for 24 h. The culture medium was replaced by medium

Figure 1. SDS-PAGE analysis of purified rhArg and rhArg-peg$_{5,000mw}$. Arginase was pegylated with mPEG-SPA in a mole ratio of 1:50 for 2.5 h. *Lane 1,* low-range protein marker; *lane 2,* native rhArg, MW ~35 kDa; *lane 3,* purified rhArg-peg$_{5,000mw}$.

with varying concentrations of either rhArg (native or pegylated) or the ADI native enzyme. The plates were incubated for an additional 3 or 7 days at 37°C in an incubator containing an atmosphere of 95% air and 5% CO$_2$. Then, 0.02 mL of MTS reagent was added to each well and the plates were incubated for another 4 h. The absorbance of the wells at 490 nm was then determined. The amount of rhArg, native or pegylated, needed to kill 50% of the cells in a culture was defined as IC$_{50}$. We used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay from Promega, which is a colorimetric method for determining the number of viable cells in proliferation assays. MTS is chemically reduced by cells to formazan, which is soluble in tissue culture medium. The measurement of the absorbance of the formazan can be carried out at 490 nm. The assay measures dehydrogenase enzyme activity found in metabolically active cells.

Amino acid analysis. Cell culture medium after treatment was collected and mixed with 50% trichloroacetic acid for precipitation of protein by incubating on ice for 30 min. The samples were centrifuged at 13,000 × *g* for 15 min, and arginine and ornithine levels were analyzed by high-speed amino acid analyzer (model L-8800, Hitachi, Tokyo, Japan) according to the manufacturer's instruction and was previously described (20). Briefly, measurements were done with an ion-exchange column, reactor temperature at 135°C, and photometer at 570 nm for detection.

Reverse transcription-PCR studies. Total RNA was extracted from cancer cell lines grown in culture using the Qiagen RNeasy kit. For reverse transcription-PCR (RT-PCR), the RNA was first reverse transcribed into cDNA by iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer's instruction. Briefly, 5 μg of total RNA were subjected to reverse transcription at 42°C for 30 min. A 2-μL portion of cDNA was then amplified using 50 μL of reaction mixture containing 0.5 unit of iTaq DNA polymerase (Bio-Rad). PCR was done in a DNA thermal MyCycler (Bio-Rad). The following flanking primers were used: ASS-S, 5′-GGGG-TCCCTGTGAAGGTGACC-3′ [from 688 to 708 nucleotides (nt)]; ASS-AS, 5′-CGTTCATGCTCACCAGCTC-3′ (from 1,117 to 1,136 nt); ASL-S, 5′-TGATGCCCCAGAAGAAAAACC-3′ (from 848 to 868 nt); ASL-AS, 5′-CATCCCTTTGCGGACCAGGTA-3′ (from 1,126 to 1,146 nt); OTC-S, 5′-TTTTCAAGGGCATAGAATCGTC-3′ (from 17 to 38 nt); OTC-AS, 5′-CTTTTCCCCATAAACCAACTCA-3′ (from 1,248 to 1,269 nt).

The reaction products were subjected to 1% agarose gel electrophoresis. After electrophoresis and staining with ethidium bromide, all PCR product band intensities were analyzed by Lumi-Imager (Boehringer Mannheim, Indianapolis, IN), and the relative mRNA expression levels were estimated by normalization with β-actin.

OTC expression construct. The coding region of the *OTC* gene was amplified from the Marathon's liver cDNA library (Clontech) at an annealing temperature of 60°C with oligonucleotides 1 and 2, which contain the recognition sites for restriction enzymes *Hin*dIII and *Eco*RI, respectively (underlined): oligo 1, 5′-CCC<u>AAGCTT</u>ATGAGGGCATAGAATCGT-3′; oligo 2, 5′-CCG<u>GAATTC</u>CTACCAACATTGCTTCTTTCT-3′.

The PCR product was digested with *Hin*dIII and *Eco*RI and ligated into *Hin*dIII/*Eco*RI–digested pcDNA3 vector (Invitrogen) to yield the OTC expression plasmid pcDNA3-OTC. The plasmid was then introduced into HCC cells by lipofection as follows: cells were plated 24 h before transfection to reach 60% to 80% confluence in 12-well plates. Plasmid DNA (1 μg), prepared using an endotoxin-free plasmid purification kit (Promega), was mixed with 4 μL of TransFectin Reagent (Bio-Rad) and incubated for 20 min at room temperature. The DNA/TransFectin complexes were directly added to cells in serum-containing medium. Following 6 h of incubation, the transfection medium was removed and the complete medium was added. The expression of the *OTC* gene in transfected HCC cells was verified by RT-PCR analysis using the primers described above. These transfected cells were then analyzed again for sensitivity to rhArg-peg$_{5,000mw}$ treatment for 3 days with MTS reagent.

OTC enzyme activity assay. Cells were harvested, washed, and suspended in 0.1 mol/L Tris-HCl (pH 7.5). Extraction of cell proteins was accomplished by incubating the cells with CelLytic MT reagent (Sigma) for 15 min on a shaker. Cell lysate was centrifuged and the supernatant was transferred to clean tubes on ice. OTC activity was measured as the rate of citrulline formation from ornithine and carbamyl phosphate as described by Marshall and Cohen (25). Briefly, the standard assay mixture (3 mL) contained 8 mmol/L Tris-HCl buffer (pH 8.5), 5 mmol/L ornithine, 5 mmol/L carbamoyl phosphate, and cell extract. The ornithine and carbamyl phosphate solutions were prepared just before use. The reaction was started by adding the carbamoyl phosphate solution and was allowed to continue for 15 min at 37°C. Subsequently, the reaction was stopped by the addition of 3 mL of 6.25% (w/v) trichloroacetic acid solution. The concentration of citrulline in the mixture was measured by adding 1 mL of the test solution into 2,3-butanedione monoxime/acid solution (1:3, v/v). They were mixed by swirling and the tubes were transferred to boiling water bath and incubated for 20 min. Distilled water (8 mL) was added and absorbance was measured at 490 nm. Standard curves were constructed by appropriately diluting a stock solution of citrulline. One unit of OTC would form 1 μmol of citrulline from ornithine and carbamyl phosphate per minute at pH 8.5 and 37°C.

Pharmacodynamics of rhArg-peg$_{5,000mw}$. Sprague-Dawley rats were obtained from the Chinese University of Hong Kong (Shatin, Hong Kong) for use in the pharmacodynamic studies. Normal Sprague-Dawley rats (four females and four males), ~3 months old (average body weight, ~250 g), were recruited and were randomly assigned into groups. Different dosages of rhArg-peg$_{5,000mw}$ (500, 1,000, 1,500, and 3,000 IU per rat) were given i.p. on day 0. Blood samples were drawn from their tail veins on day 0 before the i.p. injection of rhArg-peg$_{5,000mw}$, as baseline, on days 1 to 6, and then every 2 days. Blood was collected in EDTA and mixed with 50% trichloroacetic acid for precipitation of protein by incubating on ice for 30 min. The samples were centrifuged at 13,000 × *g* for 15 min, and arginine level in the clear supernatant fraction was analyzed by high-speed amino acid analyzer (model L-8800, Hitachi). The plasma arginine levels at the indicated time points were determined using the amino acid analyzer as described by Cheng et al. (20).

Implantation of tumor cells in nude mice. The BALB/c nude mice used in this study were obtained from the Chinese University of Hong Kong and were all males, 3 weeks old (average body weight, ~20 g), at the beginning of the study. They were used in the *in vivo* drug efficacy tests of rhArg-peg$_{5,000mw}$. They were provided with standard mouse chow and water *ad libitum*. Hep3B cells were removed from the tissue culture flasks with trypsin in Dulbecco's PBS (Invitrogen Life Technologies) and resuspended in growth medium. Approximately 1 million cells were injected s.c. near the right axilla of each mouse. Once the initial solid tumor was established in mice, it was then maintained by serial passage of 30 to 40 mg of tumor fragments implanted s.c. near the axilla. When

the volume-doubling time was stabilized, the xenografts were then used for drug evaluation.

***In vivo* efficacy of rhArg-peg$_{5,000mw}$ on nude mice bearing HCC xenografts and its synergy with 5-FU.** Forty male nude mice (average body weight, ~ 20 g) were implanted with 3-mm solid tumors, which were allowed to grow until they reached an average diameter of 5 mm. The mice were then randomly divided into four groups (10 mice per group) and were treated i.p. once a week as follows: group 1, administered with 0.2 mL of 0.9% normal saline (control) per mouse; group 2, administered with 250 IU rhArg-peg$_{5,000mw}$ per mouse; group 3, administered with 250 IU rhArg-peg$_{5,000mw}$ per mouse and 10 mg/kg 5-FU; and group 4, administered with 10 mg/kg 5-FU.

The solid tumors in each animal were observed *in situ* once every 2 days by digital caliper measurements to determine the tumor size and weight.

The size of tumor was calculated by the average of two perpendicular diameters and one diagonal diameter.

Statistical analysis. Statistical analysis was done with SPSS 11.0 software (SPSS, Chicago, IL). The differences in tumor sizes were determined by two-tailed Student's *t* test.

Results

***In vitro* arginine-degrading activity of rhArg-peg$_{5,000mw}$.** Figure 1 clearly shows that the rhArg native enzyme was very efficiently pegylated to form rhArg-peg$_{5,000mw}$ by the method we used. As can be seen from the SDS-PAGE data, the molecular weight of the pegylated rhArg-peg$_{5,000mw}$ was much higher than


Figure 2. Arginine (*A*) and ornithine (*B*) levels in Hep3B cell culture medium after treatment with rhArg-peg$_{5,000mw}$ for variable durations. Medium was collected after incubation with rhArg-peg$_{5,000mw}$, the protein was precipitated, and amino acid analysis of the supernatant was done with amino acid analyzer.

Table 1. Arginase inhibition of HCC cell lines *in vitro*

Tumor cell lines	Native rhArg IC$_{50}$ (IU/mL)	Pegylated rhArg-peg$_{5,000mw}$ IC$_{50}$ (IU/mL)	OTC activity (units/mg protein)
HepG2	0.20	0.24	Undetectable
Hep3B	0.10	0.10	Undetectable
PLC/PRF/5	0.21	0.21	Undetectable
Huh7	0.23	0.21	Undetectable
SK-HEP-1	0.25	0.22	Undetectable
HeLa	0.35	0.28	Undetectable
WiDr	>100	>100	0.120
A549	>100	>100	0.115

NOTE: The cells listed were grown in 96-well plates for 24 h and then challenged with 0 to 100 IU/mL of either the rhArg native enzyme or the rhArg-peg$_{5,000mw}$ pegylated enzyme. After additional 3 d of incubation, viability of the cells was determined using MTS reagent, and the IC$_{50}$ values were determined. Several other human tumor cell lines were tested by the same method, including a human colorectal (WiDr) and a human lung cancer (A549), all of which were able to grow in the presence of 100 IU/mL, the highest concentration tested.

that of the rhArg native enzyme. Amino acid analysis of the culture medium contents showed that arginine was decreased, corresponding to an increase in ornithine level, indicating efficient enzymatic conversion of arginine to ornithine by rhArg-peg$_{5,000mw}$ in the culture medium (Fig. 2*A* and *B*). Asparaginase, which is currently used in the treatment of acute lymphoblastic leukemia, degrades both asparagines and glutamine (26). Its deleterious side effects were due to its degradation of glutamine (27). In contrast, the action of rhArg-peg$_{5,000mw}$ was specific in that we found no evidence of degradation of other amino acids (data not shown). Ensor et al. (12) had reported that native ADI and pegylated ADI only degrade arginine but not other amino acids.

Inhibition of human HCC cell lines with the rhArg native enzyme and the rhArg-peg$_{5,000mw}$ pegylated enzyme. Five HCC cell lines (HepG2, Hep3B, PLC/PRF/5, Huh7, and SK-HEP-1) were each incubated for 3 days with either native or pegylated rhArg to test their *in vitro* sensitivities to the enzyme (Table 1). Strikingly, all the HCC cell lines tested were sensitive to the rhArg native enzyme *in vitro* with IC$_{50}$ values between 0.10 and 0.25 IU/mL. Hep3B was the most sensitive tumor with an IC$_{50}$ of 0.10 IU/mL. Similar results were seen when rhArg-peg$_{5,000mw}$ was used, indicating that both the native rhArg and the pegylated rhArg (rhArg-peg$_{5,000mw}$) have similar antitumor efficacy *in vitro*. On the other hand, HeLa cells (cervix adenocarcinoma) were also found to be sensitive to both rhArg and rhArg-peg$_{5,000mw}$ with IC$_{50}$ values between 0.28 and 0.35 IU/mL. However, a human colorectal adenocarcinoma cell line (WiDr) and a human lung cancer cell line (A549) were resistant to rhArg and rhArg-peg$_{5,000mw}$ treatment with IC$_{50}$ values >100 IU/mL, the highest concentration tested.

Next, we compared the *in vitro* efficacy of an established arginine-depleting enzyme, the ADI native enzyme, with the rhArg native enzyme on two HCC cell lines (HepG2 and Hep3B) and a melanoma cell line (SK-MEL-28; Table 2). Again, the rhArg native enzyme was highly effective against these cell lines, with IC$_{50}$ values between 0.10 and 0.20 IU/mL (or 0.35 and 0.70 µg/mL). Unexpectedly, HepG2 and Hep3B were highly resistant to the ADI native enzyme with IC$_{50}$ values well over 10 IU/mL (or 217 µg/mL). On the other hand, the SK-MEL-28 melanoma cell line was sensitive to ADI as well as to rhArg.

Expression of ASS, ASL, and OTC mRNA in tested cell lines. The mRNA products of the five HCC cell lines (HepG2, Hep3B,

PLC/PRF/5, Huh7, and SK-HEP-1), as well as of four other cell lines (HeLa, WiDr, A549, and SK-MEL-28), were measured by RT-PCR. We were surprised that they all showed detectable and variable amounts of ASS and ASL mRNA (Fig. 3*A*). However, the melanoma cells (SK-MEL-28) did not produce detectable amount of ASS mRNA, consistent with previously published data (12). Intriguingly, OTC mRNA was not detected in most cell lines (Fig. 3*A*), except the colorectal (WiDr) and lung cancer (A549) cell lines, which were resistant to rhArg-peg$_{5,000mw}$, even in the presence of high concentrations (100 IU/mL) of rhArg-peg$_{5,000mw}$ (Table 1). In addition, OTC enzyme activity was undetectable in the cells that were sensitive to rhArg-peg$_{5,000mw}$. More importantly, OTC activity was detected in WiDr and A549, consistent with the RT-PCR results (Table 1). Thus, all OTC-negative cancer cell lines were much more sensitive to both rhArg and rhArg-peg$_{5,000mw}$ than OTC-positive cell lines and these cells exhibited a range of sensitivity to both rhArg and rhArg-peg$_{5,000mw}$, with IC$_{50}$s ranging from 0.10 to 0.35 IU/mL (or 0.35–1.23 µg/mL).

OTC transfection of the HCC cell lines HepG2, PLC/PRF/5, and Huh7 and reversal of sensitivity to rhArg-peg$_{5,000mw}$. To confirm that it was the deficiency of OTC that caused sensitivity to rhArg or rhArg-peg$_{5,000mw}$ treatment, OTC mRNA-deficient cells were transfected with an expression plasmid carrying the OTC cDNA. Figure 3*B* clearly shows that OTC-transfected HepG2, PLC/PRF/5, and Huh7 cell lines expressed the *OTC* gene. These cell lines were grown in 96-well plates and incubated with rhArg-peg$_{5,000mw}$ of various concentrations. After 3 days, the growth of the cells was

Table 2. A comparison between the IC$_{50}$ values of the rhArg native enzyme and the ADI native enzyme on HepG2, Hep3B, and the human melanoma cell line SK-MEL-28

| Tumor cell lines	Native ADI IC$_{50}$ (IU/mL)	Native rhArg IC$_{50}$ (IU/mL)
HepG2	>10 (>217 µg/mL)	0.20 (0.70 µg/mL)
Hep3B	>10 (>217 µg/mL)	0.10 (0.35 µg/mL)
SK-MEL-28	0.0067 (0.13 µg/mL)	0.12 (0.42 µg/mL)

Figure 3. *A,* expression of ASS, ASL, and OTC mRNA in cultured cells. *Lane 1,* HepG2; *lane 2,* Hep3B; *lane 3,* PLC/PRF/5; *lane 4,* Huh7; *lane 5,* HeLa; *lane 6,* SK-HEP-1; *lane 7,* WiDr; *lane 8,* A549; and *lane 9,* SK-MEL-28. Semiquantitative RT-PCR was used to determine whether ASS, ASL, and OTC mRNAs were being produced. *B,* expression of OTC mRNA in HepG2 (*lanes 1* and *2*), PLC/PRF/5 (*lanes 3* and *4*), and Huh7 (*lanes 5* and *6*) transfected with human cDNA encoding OTC. HCC cell lines were transfected with expression plasmid pcDNA3 carrying the human *OTC* gene. RNA was isolated from the parental cells (*lanes 1, 3,* and *5*) and transfected cells (*lanes 2, 4,* and *6*). RT-PCR was used to determine whether OTC mRNA was being produced.

measured with the MTS reagent. The cells transfected with the *OTC* gene were much more resistant to rhArg-peg$_{5,000mw}$ than the untransfected parental cells *in vitro* (Table 3). This suggested that OTC deficiency increased the sensitivity of these HCC cell lines to rhArg-peg$_{5,000mw}$ treatment. The results indicate that OTC expression alone may be sufficient to induce rhArg-peg$_{5,000mw}$ resistance in ASS-positive HCC cells.

Pharmacodynamic study of rhArg-peg$_{5,000mw}$ in rats. The effects of injection of rhArg-peg$_{5,000mw}$ on the plasma levels of arginine (the pharmacodynamics) were determined by administering rhArg-peg$_{5,000mw}$ to rats. As shown in Fig. 4, rhArg-peg$_{5,000mw}$ depleted the plasma arginine in rats in a dose-dependent manner. Administration of rhArg-peg$_{5,000mw}$ resulted in an immediate lowering of plasma arginine to zero on day 1 and, thereafter, arginine levels returned to normal level in the next 10+ days. A dose of 1,500 IU per rat (or 6 IU/g of rat) seemed to lower arginine levels to about zero for 4 to 5 days. This was deemed as the weekly optimal biological depletion dose for rats. As mice have a faster metabolic rate than rats, we estimated the weekly optimal biological depletion dose for mice to be approximately twice that for rats [i.e., ~ 250 IU per mouse (or 12 IU/g of mouse)].

Ensor et al. (12) reported that the circulation half-life of ADI (a few hours) was prolonged by pegylation. The pegylated ADI had a circulation half-life of a few days. Although the native ADI enzyme and the pegylated ADI were similar in their ability to inhibit the growth of melanoma and HCCs *in vitro*, only the pegylated ADI was found to be effective in inhibiting the growth of these tumor cells *in vivo*. It would seem that to achieve efficacy *in vivo*, serum arginine levels must be maintained at low levels for some time.

***In vivo* efficacy of rhArg-peg$_{5,000mw}$ on human HCC implanted in mice.** The *in vivo* efficacy of rhArg-peg$_{5,000mw}$ on nude mice bearing human HCC xenograft was tested. The OTC-deficient Hep3B cell line (ASS-positive and ADI-resistant) was chosen for this study. In the control group, saline was used and progressive tumor growth was observed. In the treatment groups, rhArg-peg$_{5,000mw}$ was found to have significant tumor-retarding activity in Hep3B (Fig. 5), with early divergence of the tumor size curves, which seemed to parallel each other after the second or third week (P = 0.048). Intriguingly, the combination of 5-FU with rhArg-peg$_{5,000mw}$ seemed to augment the tumor regression rate on this HCC tested.

Discussion

Of all the amino acids, essential and nonessential, depletion of arginine causes the greatest havoc to the cells, in particular tumor cells. Because of their intact "R" checkpoint in the G$_1$ phase of the cell cycle, normal cells generally enter into quiescence (G$_0$) when depleted of arginine, awaiting the return of favorable conditions before resumption of normal cell division, a condition that many cells can tolerate for weeks. Tumor cells, on the other hand, with their defective "R" checkpoint or other cycle aberrations, continue to cycle despite the absence of arginine, which leads to gross imbalance and cell death (28). This is not unexpected because arginine occupies an extremely important position in a myriad of metabolic and enzymatic pathways (1).

For tumor cells in culture, total depletion of arginine is not survivable. Arginine is also unique in that it can be resynthesized by many somatic cells from citrulline. This is the built-in alternative arginine source of the body to ensure its survival in case the amino acid is in short supply or deficient (1). *In vitro* arginine depletion, whether through an arginine-degrading enzyme, such as arginase or ADI, or by using arginine-free medium, is particularly tumoricidal in those tumors that are highly dependent on exogenous arginine for growth (19). *In vivo*, enzymatic depletion of arginine offers the most logical and relatively simple approach to

Table 3. IC$_{50}$ values of rhArg-peg$_{5,000mw}$ on HCCs transfected with human cDNA encoding OTC

OTC-transfected HCCs	rhArg-peg$_{5,000mw}$ IC$_{50}$ (IU/mL)
OTC-HepG2	>20
OTC-PLC/PRF/5	>100
OTC-Huh7	>10

NOTE: Human HCCs HepG2, PLC/PRF/5, and Huh7 were transfected with an expression plasmid carrying the human cDNA encoding OTC under the constitutive expression of the cytomegalovirus promoter. The transfected cells were incubated with rhArg-peg$_{5,000mw}$ for 3 d and the viability of cells was measured by MTS assay.

Figure 4. The pharmacodynamic of rhArg-peg$_{5,000mw}$ on plasma arginine in rats. Sprague-Dawley rats were each injected i.p. with various concentrations of rhArg-peg$_{5,000mw}$ (●, 500 IU per rat; ○, 1,000 IU per rat; ▼, 1,500 IU per rat; △, 3,000 IU per rat). Plasma was collected at the indicated time points and the amount of arginine in each sample was determined by amino acid analysis. Means of five animals per dose.

arginine depletion. HCC and malignant melanoma are often auxotrophic for arginine (19). The mechanism of this arginine auxotrophy has been amply described in a number of reports (3, 15, 19, 29–31). In essence, these tumors reportedly lack ASS with which to regenerate arginine, which is indispensable for growth. This absolute dependence on exogenous arginine in these tumors makes them particularly vulnerable to arginine depletion (19, 29, 31).

ADI in its pegylated form, ADI-SS PEG$_{20,000mw}$ (12, 32), has now been shown to have *in vitro* and *in vivo* activities in HCC and malignant melanoma as reported in the recent phase II studies

(9, 10), although it does have a number of shortcomings. First, it is a bacterial enzyme and antigenicity may still be a problem despite pegylation. In phase II studies that have been reported, autoantibodies were detected as early as the 5th week and continued to increase with treatment (9, 10). This may potentially render the drug ineffective on prolonged treatment. Second, ADI converts arginine to citrulline and free ammonia, which could pose problems in patients with cirrhosis liver and hepatic decompensation with further elevation of ammonia levels (33), leading to prehepatic encephalopathy in man (9, 10, 19). Third, ADI product citrulline is readily recyclable and rescues cells not only from

Figure 5. Effects of rhArg-peg$_{5,000mw}$ on the growth of HCC implanted in nude mice. Mice were implanted with the Hep3B human HCC. Approximately 10^6 cells were injected s.c. into each mouse, and the tumors were allowed to grow until they reached ~5 to 10 mm in diameter. The animals were then randomly assigned into two groups (10 animals were implanted with each tumor in each treatment group). Mice were then treated once a week for 2 mo with either saline (●), 250 IU of rhArg-peg$_{5,000mw}$ (○), 5-FU (▼), or combination of rhArg-peg$_{5,000mw}$ and 5-FU (▽). The size of the tumors was measured once every 2 d and the results are shown as fold increase in tumor size.

arginine-free medium but also from arginase-induced deficiency (34). This has led to the major limitation of ADI: it only kills cancer cells that are ASS deficient (9–12). Many cell lines are ASS positive and they are resistant to ADI treatment, although most require arginine for proliferation (14, 35).

Arginase is a good enzyme to use to degrade arginine in culture because its product is ornithine, which cannot be recycled to arginine because the urea cycle is incomplete in most cultured cells (34), but the mechanism for this phenomenon has been an unresolved area. In our present studies, both native and pegylated rhArg (Fig. 1) were highly active *in vitro* against all HCC cell lines, with IC_{50} values <0.3 IU/mL (Table 1). At a concentration between 0.3 and 0.4 IU/mL, rhArg-peg$_{5,000mw}$ usually achieved maximal cell kill within ~72 h. However, it was apparent that not all the HCC cell lines exhibited the same degree of sensitivity to rhArg, with Hep3B being most sensitive (IC_{50}, 0.10 IU/mL) and HepG2 least sensitive (IC_{50}, 0.24 IU/mL). Although the majority of the HCC cells died within 72 h, it was also apparent that some residual cells were still viable after this period of depletion. It is possible that once a critical level of arginine depletion is achieved, all the sensitive clones would have been totally annihilated, leaving behind residual cells that are relatively resistant to arginine depletion. Even when higher concentrations of arginase were added to complete the arginine depletion, no further cell kill was observed. This is consistent with our *in vivo* data (Fig. 5). When nude mice bearing HCC xenograft were treated with rhArg-peg$_{5,000mw}$, there was a clear and rapid separation of the tumor size curves in the first 2 to 3 weeks, suggesting rapid killing of the sensitive clones. Thereafter, the curves seemed to diverge more slowly, suggesting continuous growth of a resistant clone of tumor cells. The mechanism of this relative resistance to arginine depletion awaits further elucidation.

Conceptually, the addition of cycle-dependent drugs such as 5-FU along with rhArg-peg$_{5,000mw}$ might augment the antitumor effect of rhArg-peg$_{5,000mw}$ by eradicating some of the resistant clones from the outset, in much the same way as acute lymphoblastic leukemia is treated with L-asparaginase and other cytotoxic agents (36). 5-FU also interferes with RNA and DNA synthesis (37). We used a very low concentration of 5-FU (10 mg/kg) such that this drug alone could not inhibit tumor growth. We were surprised that growth inhibition of HCC tumor cells was enhanced by the combined treatment of pegylated rhArg and 5-FU (Fig. 5). Arginase, in its pegylated form to enhance its arginine depletion activity, could be used as a means to destabilize cancer cells (in our case, HCC) so as to cause a perturbation in their cell cycling. This could account for the enhanced activity of 5-FU *in vivo*. The possible mechanisms of synergy will be investigated in future studies. Thus, our data suggest that rhArg-peg$_{5,000mw}$ is a novel agent for effective cancer therapy.

The efficacy of combination treatment has already been shown with hydroxyurea given along with arginase (15). There are now ongoing nude mice preclinical studies in our laboratory to test different treatment chemotherapy combinations together with rhArg-peg$_{5,000mw}$ to try and establish the most effective treatment combination. These data could serve as the scientific basis for the design of future phase III clinical studies.

When comparing the *in vitro* cytotoxic activities of the ADI native enzyme with the rhArg native enzyme, it was surprising to find that ADI was totally ineffective in all our HCC cell lines whereas rhArg remained highly effective (Table 2). The ADI native enzyme was effective on the SK-MEL-28 melanoma cell line, indicating that the ADI we used was functionally active. Ensor et al.

(12) reported that there was a relatively wide range of sensitivity to ADI exhibited by ASS-negative cells, with IC_{50}s ranging from <0.01 to 0.3 µg/mL. Furthermore, our results showed that the rhArg IC_{50}s were 0.42 µg/mL for melanoma (SK-MEL-28) and 0.35 to 0.70 µg/mL for HCCs (HepG2 and Hep3B). Therefore, rhArg inhibited both melanoma and HCCs efficiently and it killed HCCs that could not be killed by ADI.

The reason for the inability of ADI to kill the HCC cells was immediately apparent from the gene profiles of these cell lines with regard to their ASS and ASL gene expression. Contrary to expectation, ASS levels were found to be uniformly present in all the cell lines tested (Fig. 3A), except SK-MEL-28. This would therefore explain the ineffectiveness of ADI on the HCC cell lines that we selected for study. This positive expression of ASS also indicated that the antitumor mechanism of rhArg and rhArg-peg$_{5,000mw}$ was independent of ASS expression. This turned our attention to OTC, which catalyzes the conversion of ornithine to citrulline. Again, we unexpectedly found that OTC mRNA was absent in all the HCC cell lines (Fig. 3A) and OTC enzyme activity was undetectable (Table 1). Because OTC is responsible for the conversion of ornithine to citrulline, which is then converted to arginine via ASS and ASL, one must conclude that these HCC cell lines are auxotrophic for arginine because of their inherent lack of OTC expression. Confirmation came by transfection with the *OTC* gene into the HCC cell lines HepG2, PLC/PRF/5, and Huh7, with the cell lines becoming resistant to arginine depletion with rhArg-peg$_{5,000mw}$ (Fig. 3B; Table 3). As a positive control, we also did arginine depletion with rhArg-peg$_{5,000mw}$ on known OTC-positive cell lines, WiDr (colorectal cancer) and A549 (lung cancer), both of which are resistant to rhArg-peg$_{5,000mw}$ (Table 1). This opens up an entirely new avenue for exploration with the burgeoning interest being shown in arginine deprivation as a means of bringing cancer cells under control, but it also calls for much more work on a wide spectrum of cell lines, normal and transformed, as well as on tumor biopsy samples, because information of the expression of this OTC enzyme will give valuable information about which tumors will be sensitive, as opposed to resistant, to a therapeutic procedure involving arginine depletion.

In the case of ADI-sensitive tumors, Sugimura et al. (4) had suggested that melanomas may be sensitive to ADI as a result of their inability to express ASS. Furthermore, Ensor et al. (12) reported that only the melanoma and HCC cell lines that lack ASS mRNA were sensitive to killing by ADI. They also found that cell lines that expressed ASS were resistant to ADI and were able to grow even in the presence of large amounts (100 µg/mL) of ADI. Because citrulline is converted to arginine by the sequential actions of ASS and ASL, an inability to express either enzyme would be expected to result in arginine auxotrophy and sensitivity to ADI. All the melanoma and HCC cell lines studied by Ensor et al. (12) did not produce detectable amounts of ASS mRNA but produced ASL mRNA. On the other hand, ornithine is converted to arginine by the sequential actions of OTC, ASS, and ASL, and all the cell lines tested thus far are ASL positive (Fig. 3A). Therefore, an inability to express either OTC or ASS would be expected to result in arginine auxotrophy and sensitivity to rhArg. Thus far, it is not known why human HCCs are unable to express OTC. It will be interesting to study the *OTC* gene structure and the promoter region to understand the molecular details. The use of pegylated rhArg to kill OTC-deficient, ASS-positive tumors has opened up many anticancer drug research and development possibilities.

In conclusion, we believe that the previous dogma that arginase is a poor drug candidate has now been disproved by our *in vitro* data as well as our *in vivo* HCC xenograft–bearing nude mice treated with rhArg-peg$_{5,000mw}$. RhArg-peg$_{5,000mw}$ is potentially a better drug candidate than the pegylated ADI (ADI-SS PEG$_{20,000mw}$) because of its predicted efficacy in both ASS-negative and OTC-negative tumors whereas ADI-SS PEG$_{20,000mw}$ only works in ASS-negative tumors. RhArg-peg$_{5,000mw}$ may be a safer drug candidate than ADI-SS PEG$_{20,000mw}$ with no free ammonia as a side product. Being a pegylated human hepatic enzyme, rhArg-peg$_{5,000mw}$ should be less immunogenic when compared with ADI-SS PEG$_{20,000mw}$. We hope our studies will initiate a revival of interests in arginase research, in particular in the quest for a better arginine-depleting agent for the treatment of human malignancies.

References

1. Wu G, Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1–17.
2. Gonzalez GG, Byus CV. Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res 1991;51:2932–9.
3. Morris SM, Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22:87–105.
4. Sugimura K, Ohno T, Kusuyama T, Azuma I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase *in vitro*. Melanoma Res 1992;2:191–6.
5. Bach SJ, Hawkins RA, Swaine D. A short method for the purification of arginase from ox liver. Biochem J 1963;89:263–5.
6. Currie GA, Gyure L, Cifuentes L. Microenvironmental arginine depletion by macrophages *in vivo*. Br J Cancer 1979;39:613–20.
7. Storr JM, Burton AF. The effects of arginine deficiency on lymphoma cells. Br J Cancer 1974;30:50–9.
8. Takaku H, Matsumoto M, Misawa S, Miyazaki K. Antitumor activity of arginine deiminase from *Mycoplasma argini* and its growth-inhibitory mechanism. Jpn J Cancer Res 1995;86:840–6.
9. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815–22.
10. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660–8.
11. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826–33.
12. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG$_{20,000\ mw}$) inhibits human melanomas and hepatocellular carcinomas *in vitro* and *in vivo*. Cancer Res 2002;62:5443–50.
13. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 2006;15:815–22.
14. Shen LJ, Lin WC, Beloussow K, Shen WC. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 2003;191:165–70.
15. Wheatley DN. Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs 2004;15:825–33.
16. Savoca KV, Abuchowski A, van Es T, Davis FF, Palczuk NC. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochim Biophys Acta 1979;578:47–53.
17. Savoca KV, Davis FF, van Es T, McCoy JR, Palczuk NC. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia. Cancer Biochem Biophys 1984;7:261–8.
18. Takaku H, Takase M, Abe S, Hayashi H, Miyazaki K. *In vivo* anti-tumor activity of arginine deiminase purified from *Mycoplasma arginini*. Int J Cancer 1992;51:244–9.
19. Wheatley DN, Campbell E. Arginine catabolism, liver extracts and cancer. Pathol Oncol Res 2002;8:18–25.
20. Cheng PN, Leung YC, Lo WH, Tsui SM, Lam KC. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett 2005;224:67–80.
21. Cheng NM, Leung YC, Lo WH. Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation. US Patent no. 20050244398. 2005 November 3.
22. Ikemoto M, Tabata M, Murachi T, Totani M. Purification and properties of human erythrocyte arginase. Ann Clin Biochem 1989;26:547–53.
23. Noh EJ, Kang SW, Shin YJ, et al. Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int J Cancer 2004;112:502–8.
24. Nag A, Mitra G, Ghosh PC. A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate. Anal Biochem 1996;237:224–31.
25. Marshall M, Cohen PP. Ornithine transcarbamylase from *Streptococcus faecalis* and bovine liver. I. Isolation and subunit structure. J Biol Chem 1972;247:1641–53.
26. Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res 1969;29:183–7.
27. Durden DL, Distasio JA. Comparison of the immunosuppressive effects of asparaginases from *Escherichia coli* and *Vibrio succinogenes*. Cancer Res 1980;40:1125–9.
28. Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000;83:800–10.
29. Wheatley DN, Campbell E. Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells. Br J Cancer 2003;89:573–6.
30. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol 2005;15:247–53.
31. Wheatley DN, Kilfeather R, Stitt A, Campbell E. Integrity and stability of the citrulline-arginine pathway in normal and tumour cell lines. Cancer Lett 2005;227:141–52.
32. Shen LJ, Shen WC. Drug evaluation: ADI-PEG-20-a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr Opin Mol Ther 2006;8:240–8.
33. van Rijn J, van den Berg J, Schipper RG, et al. Induction of hyperammonia in irradiated hepatoma cells: a recapitulation and possible explanation of the phenomenon. Br J Cancer 2004;91:150–2.
34. Wheatley DN, Philip R, Campbell E. Arginine deprivation and tumour cell death: arginase and its inhibition. Mol Cell Biochem 2003;244:177–85.
35. Sugimura K, Kimura T, Arakawa H, et al. Elevated argininosuccinate synthetase activity in adult T leukemia cell lines. Leuk Res 1990;14:931–4.
36. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003;123:836–41.
37. Holland JF, Frei MI, Pizzorno G, Cheng YC. Pyrimidine and purine antimetabolites. In: Handschumacher RE, editor. Cancer medicine. Baltimore (MD): Williams & Wilkins: 1997. p. 925–8.

Pegylated Recombinant Human Arginase (rhArg-peg 5,000mw) Inhibits the *In vitro* and *In vivo* Proliferation of Human Hepatocellular Carcinoma through Arginine Depletion

Paul Ning-Man Cheng, Tin-Lun Lam, Wai-Man Lam, et al.

Updated version	Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/67/1/309

Cited articles	This article cites 33 articles, 8 of which you can access for free at: http://cancerres.aacrjournals.org/content/67/1/309.full#ref-list-1
Citing articles	This article has been cited by 17 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/67/1/309.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/67/1/309. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.